Table 2. Prognostic significance of Oct-4 expression for OS in patients with NSCLC.
| Groups of outcomes | N | No. samples | Heterogeneity (I2, P) | Model | HR (95% CI) | P value | Conclusion | ||
|---|---|---|---|---|---|---|---|---|---|
| Total | PE | NE | |||||||
| Overall | 8 | 707 | 377 | 330 | 15.1%, 0.308 | Fixed | 3.030 (2.283–4.021) | <0.001 | Significant |
| Statistical analysis | |||||||||
| Multivariate analysis | 2 | 259 | 144 | 115 | 0.0%, 0.431 | Fixed | 2.175 (1.423–3.326) | <0.001 | Significant |
| Univariate analysis | 6 | 448 | 233 | 215 | 0.0%, 0.597 | Fixed | 3.948 (2.701–5.770) | <0.001 | Significant |
| Origins of patients | |||||||||
| China mainland | 5 | 436 | 189 | 247 | 15.3%, 0.316 | Fixed | 3.564 (2.484–5.113) | <0.001 | Significant |
| Taiwan | 3 | 271 | 188 | 83 | 0.0%, 0.471 | Fixed | 2.340 (1.484–3.690) | <0.001 | Significant |
| Positive-staining sites | |||||||||
| Nucleus | 4 | 310 | 137 | 173 | 2.4%, 0.393 | Fixed | 4.301 (2.733–6.767) | <0.001 | Significant |
| Non-nucleus | Given up because of the scarcity of available data | ||||||||
| Histological subtypes1 | |||||||||
| AC | 3 | 196 | 133 | 63 | 36.4%, 0.208 | Fixed | 4.108 (2.166–7.790) | <0.001 | Significant |
| SCC | 1 | 52 | 17 | 35 | – | – | 3.822 (1.084–13.470) | 0.037 | Significant |
1, the clinical data of each histological subtypes of NSCLC was only reported in (13,18,19). AC, adenocarcinoma; CI, confidence interval; HR, hazard ratio; NE, negative expression; NSCLC, non-small cell lung cancer; Oct-4, octamer-binding transcription factor 4; OS, overall survival; PE, positive expression; SCC, squamous cell carcinoma.